ReviewInternational journal of molecular sciences2015
A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 62 citations in OpenAlex.
- Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients.Clinical and experimental immunology · 2020Trial
- Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.The Journal of clinical investigation · 2019Trial
- Innate immune regulation of adaptive immunity: mechanisms, implications, and bias.Frontiers in immunology · 2026Review
- Bronchus-associated lymphoid tissue: a review of its development and function, including recent findings on the impact of environmental particulate exposure.Clinical and experimental medicine · 2025Review
- Markers of Antiviral Response in SLE Patients After Vaccination Against SARS-CoV-2.International journal of molecular sciences · 2025Article
- Review
- Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities.Kidney international reports · 2025Review
- A Transcriptome Array-Based Approach Links Proteinuria and Distinct Molecular Signatures to Intrarenal Expression of Type I InterferonInternational journal of molecular sciences · 2023Article
- Review
- Emerging Therapies in Cutaneous Lupus Erythematosus.Frontiers in medicine · 2022Review
- New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination.Case reports in rheumatology · 2022Article
- Letter to the editor regarding the article ''Patil S, Patil A. Systemic lupus erythematosus after COVID-19 vaccination: A case report. J Cosmet Dermatol. 2021 Aug 21. 10.1111/jocd.14386".Journal of cosmetic dermatology · 2021Article
- Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update.Clinical rheumatology · 2021Review
- Review
- Immunological Involvement of MicroRNAs in the Key Events of Systemic Lupus Erythematosus.Frontiers in immunology · 2021Review
- Mutation inFrontiers in immunology · 2021Article
- Aberrant Non-Coding RNA Expression in Patients with Systemic Lupus Erythematosus: Consequences for Immune Dysfunctions and Tissue Damage.Biomolecules · 2020Review
- Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.Nature genetics · 2020Article
- Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis.Cytokine · 2020Review
- Are lupus animal models useful for understanding and developing new therapies for human SLE?Journal of autoimmunity · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by the generation of immune responses to various nuclear components. Impaired clearance of apoptotic cells and loss of tolerance to self-antigens are involved both in the initiation and in the propagation of the disease. Dendritic cells (DCs) are key factors in the balance between autoimmunity and tolerance and play a role linking innate and adaptive immunity. DCs, particularly plasmacytoid DCs (pDCs), are the main source of type I interferon (IFN) cytokines, which contribute to the immunopathogenesis of SLE. There is accumulating evidence that pDCs and type I IFN cytokines take the leading part in the development of SLE. In this review, we discuss recent data regarding the role of pDCs and type I IFN cytokines in the pathogenesis of SLE and the potential for employing therapies targeting against aberrant regulation of the pDC-type I IFN axis for treating SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.